Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.

Anticancer Bioscience Ltd. has identified compounds potentially useful for the treatment of cancer.

Scientists at Daegu-Gyeongbuk Medical Innovation Foundation and Korea Research Institute of Chemical Technology have synthesized phenaleno-isoquinolinium-based compounds reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has divulged compounds acting as histone deacetylase 1 (HDAC1) and/or 2 (HDAC2) inhibitors reported to be useful for the treatment of cancer.

Researchers at Inventisbio Co. Ltd. and Inventisbio LLC have described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

The immunological targeting of cold tumors still remains a challenge. Cytokine therapy is promising but has modest efficacy and significant toxicity.

Beijing Double-Crane Runchuang Technology Co. Ltd. has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Avelos Therapeutics Inc. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Beigene Switzerland GmbH has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Nanjing Mingde New Drug Research Co. Ltd. has designed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety via a linker for the treatment of cancer.